Recently Updated Pages
170 - Summary of monitoring
Summary of monitoring
17 - Recommendations
Recommendations
169 - Clinical management of dyslipidaemia
Clinical management of dyslipidaemia 170 The Maudsley® Prescribing Guidelines in Psychiatry CHAPT...
168 - Screening and monitoring
Screening and monitoring
167 - Clozapine
Clozapine
166 - Olanzapine
Olanzapine Schizophrenia and related psychoses CHAPTER 1 Effects of antipsychotic medications on ...
165 - Effect of antipsychotic medications on lipids
Effect of antipsychotic medications on lipids
164 - Effects of antipsychotic medications on plasm
Effects of antipsychotic medications on plasma lipids
163 - References
References 166 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Other cardiovascular ...
162 - Summary
Summary
161 - Other cardiovascular risk factors
Other cardiovascular risk factors
160 - Metabolic inhibition
Metabolic inhibition Schizophrenia and related psychoses CHAPTER 1 Table 1.37 Non-psychotropics...
16 - Adverse effects
Adverse effects 18 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 A small number of...
159 - ECG monitoring
ECG monitoring
158 - Other risk factors
Other risk factors 164 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Aripiprazole ...
157 - Quantifying risk
Quantifying risk 162 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 ■ ■There is som...
156 - Other ECG changes
Other ECG changes
155 - QT prolongation
QT prolongation Schizophrenia and related psychoses CHAPTER 1 ECG changes – QT prolongation Intro...
154 - Introduction
Introduction
153 - ECG changes QT prolongation
ECG changes – QT prolongation